Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / Beta thalassemia
Other

Beta thalassemia

Tracked across 1 events · 8 articles · First seen Jun 02, 2026 · Last active Jun 02, 2026

Sentiment
70
Attention
6
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
6 70
Tech
CorrectSequence CS-206 Sickle Cell Data
CorrectSequence Therapeutics, a clinical-stage biotechnology company, announced positive 15-month follow-up data for its high-precision base-editing therapy, CS-206, for Sickle cell disease. The first patient treated in China, a 21-year-old woman from Nigeria, has remained free…
Impact: CorrectSequence Therapeutics has also developed CS-101 for Beta thalassemia, with successful clinical trials demonstrating its effectiveness, further solidifying the company's position in treating hemoglobinopathies.
Jun 02, 2026 · 8 articles
NEWSDESK
Track Beta thalassemia live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.